Alcohol and Liver Health: What Ethanol Actually Does Inside Your Hepatocytes

Most of what gets written about alcohol and the liver stays at the surface. "Alcohol damages the liver." "Heavy drinking leads to liver disease." These statements are true. They are also not particularly useful if you want to understand what is actually happening.

The liver is the primary site of alcohol metabolism, and the damage it accumulates from regular drinking follows a well-characterized biological pathway. Understanding that pathway tells you something more specific than "drinking is bad for the liver." It tells you where the damage comes from, how quickly it starts, and what the evidence actually shows about consumption levels that most people would consider moderate.

This article covers the mechanism in detail.

How does alcohol damage the liver? Alcohol dehydrogenase (ADH) converts ethanol to acetaldehyde in liver cells. Acetaldehyde is toxic: it forms protein adducts, triggers inflammatory signaling, and generates reactive oxygen species. A second enzyme, ALDH2, converts acetaldehyde to safe acetate, but when ethanol intake exceeds the liver's clearance capacity (roughly 10 grams per hour), acetaldehyde accumulates and the damage occurs. Separately, alcohol metabolism depletes NAD+, shutting down fat burning in the liver and causing lipid accumulation (hepatic steatosis) at two to three drinks per day in research populations.

The Primary Metabolism Pathway

When ethanol enters your bloodstream, the liver is its primary processing site. The metabolism happens in two steps, each governed by a different enzyme.

Step one: Alcohol dehydrogenase (ADH) converts ethanol into acetaldehyde. This reaction is fast and efficient. The liver prioritizes it.

Step two: Aldehyde dehydrogenase 2 (ALDH2) converts acetaldehyde into acetate. Acetate is relatively benign. It enters normal metabolic pathways and is eventually broken down to carbon dioxide and water.

The problem is step one's product: acetaldehyde.

Acetaldehyde is toxic. It is chemically reactive in ways that ethanol is not. It forms protein adducts, meaning it bonds to proteins in liver cells and alters their structure. It triggers inflammatory signaling. It generates reactive oxygen species. It is the primary reason alcohol damages the liver, not the ethanol itself.

The speed at which this happens matters. The liver processes ethanol at roughly 10 grams per hour. A standard drink contains approximately 14 grams of ethanol. The liver cannot outrun the input when you drink at anything above a very slow rate, which means acetaldehyde accumulates in hepatocytes rather than being cleared cleanly between drinks.

The ALDH2 Question

Not everyone clears acetaldehyde at the same rate. ALDH2 efficiency varies by genetics, and individuals with reduced ALDH2 activity accumulate acetaldehyde at significantly higher concentrations per drink.

This is most commonly discussed in the context of ALDH2*2, a genetic variant prevalent in East Asian populations that sharply reduces ALDH2 function. The "Asian flush" response, which includes facial redness, nausea, and rapid heart rate after even small amounts of alcohol, is caused by acetaldehyde accumulating because ALDH2 cannot clear it efficiently.

But ALDH2 variation exists beyond this single variant. Even in populations without ALDH2*2, enzyme efficiency varies. The population average for hepatic acetaldehyde clearance is not an individual guarantee.

The practical implication: the same drinking pattern produces different acetaldehyde loads in different people. This partially explains why alcohol-related liver disease does not develop uniformly across people with similar drinking histories. ALDH2 genotype is one of the strongest individual predictors of acetaldehyde exposure per drink.

Fatty Liver: Where It Starts

The first stage of alcohol-related liver disease is hepatic steatosis, commonly called fatty liver. The mechanism involves something that sounds abstract but is metabolically specific: the NAD+/NADH ratio.

Here is how it works.

Both steps in ethanol metabolism consume NAD+ and produce NADH. When ethanol metabolism is running at full speed, the liver's supply of NAD+ is depleted and NADH accumulates. This ratio shift has downstream consequences throughout hepatic metabolism.

NAD+ is required for beta-oxidation, the metabolic process by which the liver burns fat. With NAD+ depleted, beta-oxidation slows or stops. Fat that would normally be broken down instead accumulates in hepatocytes.

Simultaneously, the elevated NADH environment activates enzymes that promote fatty acid synthesis. The liver shifts from burning fat to producing it.

The result is lipid accumulation in liver cells. This is hepatic steatosis.

What makes this particularly relevant is the consumption threshold at which it occurs. Steatosis is not a disease of heavy drinkers only. Research published in journals including Hepatology and Alcohol and Alcoholism has documented hepatic steatosis at two to three drinks per day in study populations. The mechanism does not require cirrhosis-level consumption to initiate. It requires only enough alcohol to shift the NAD+/NADH ratio in a sustained way.

Fatty liver is largely reversible with abstinence. The liver's fat-processing capacity returns when ethanol metabolism is no longer consuming NAD+, and the excess lipid is cleared over weeks. This reversibility is clinically significant, but it depends on catching the problem before the next stage.

Alcoholic Steatohepatitis: When Steatosis Becomes Inflammation

When alcohol consumption continues past fatty liver, steatosis progresses to alcoholic steatohepatitis (ASH). The distinction between these two stages is not just the amount of fat present but the presence of active inflammation and hepatocyte injury.

In ASH, liver cells undergo balloon degeneration. This is the term for a specific pattern of cell swelling that occurs when cytoskeletal proteins are damaged, often by acetaldehyde adducts. Ballooned hepatocytes are dysfunctional and dying.

The immune response amplifies the damage. Kupffer cells, which are the liver's resident immune cells, are activated by acetaldehyde and by lipopolysaccharides (LPS) that cross the gut lining due to alcohol-related intestinal permeability increases. Activated Kupffer cells release inflammatory cytokines including TNF-alpha. The inflammatory environment increases oxidative stress, damages more hepatocytes, and begins to activate the cells responsible for the next stage.

ASH represents the inflection point. The tissue damage is more serious than steatosis, and continued alcohol consumption at this stage significantly accelerates the progression toward fibrosis.

Fibrosis and Cirrhosis

Chronic inflammation in the liver activates hepatic stellate cells. Under normal conditions, hepatic stellate cells are quiescent and play a role in vitamin A storage. When activated by inflammatory signals, they transform into myofibroblasts and begin producing collagen.

Collagen accumulates in the spaces around hepatocytes. As it builds up, it disrupts the normal architecture of the liver: the spatial relationships between hepatocytes, the blood sinusoids that supply them with nutrients and oxygen, and the bile ducts that carry bile out of the liver. This is hepatic fibrosis.

Continued collagen production and loss of normal tissue architecture leads to cirrhosis. Cirrhosis represents extensive, irreversible scarring. Functional liver tissue is replaced by fibrous scar tissue. The liver's capacity to perform its many roles, including detoxification, protein synthesis, and bile production, is progressively compromised.

Cirrhosis is not reversible in the way that fatty liver is. Some degree of fibrosis regression can occur with sustained abstinence and treatment, but established cirrhosis represents permanent structural damage. This is why the earlier stages matter.

The Moderate Drinking Question

The spectrum from fatty liver to cirrhosis is well-documented in heavy, chronic drinkers. The more relevant question for most people is where on that spectrum moderate consumption falls.

This is genuinely contested territory, and it is worth being specific about what the research shows and where the uncertainties are.

The steatosis threshold, as noted above, is lower than most people assume. Research has documented hepatic fat accumulation at two to three drinks per day in study populations. This is not the clinical presentation of alcoholic hepatitis. It is the earliest and most reversible stage of liver injury. But it is measurable, and it occurs at consumption levels well below what most people would categorize as heavy drinking.

The question of whether moderate drinking (typically defined as up to one drink per day for women, two for men) produces clinically significant or progressive liver disease in otherwise healthy individuals is more complicated. The short answer is that the risk exists on a spectrum, is influenced by individual genetic and metabolic factors, and increases substantially with duration and quantity.

A separate question is whether moderate drinking protects liver health compared to abstinence. This is where one of the more significant debates in alcohol epidemiology sits.

The "J-curve hypothesis" proposed that moderate drinkers have better liver health outcomes than both heavy drinkers and abstainers, forming a J-shaped relationship between consumption and liver disease risk. Some earlier observational studies appeared to support this.

The J-curve hypothesis for liver outcomes has been substantially challenged on methodological grounds. The most prominent issue is sick quitter bias: abstainer comparison groups in these studies often included former drinkers who stopped because of health problems. Comparing current moderate drinkers to a group that includes people who quit due to illness produces an apparent health advantage for moderate drinkers that may reflect group composition rather than a genuine protective effect of alcohol.

When studies attempt to use only lifetime abstainers as the comparison group, or apply Mendelian randomization methods that control for confounding, the apparent protective effect of moderate drinking diminishes or disappears.

This does not settle the question. The J-curve for liver health remains an area of active research and genuine scientific debate. What it does mean: the claim that moderate drinking protects the liver relative to abstinence is not established science. It is a hypothesis with contested evidence, and the methodological challenges to the supporting studies are substantial. Rate this area MODERATE confidence in either direction.

What 0.5% ABV Means for This Pathway

Understanding the liver metabolism pathway makes the 0.5% ABV question answerable in specific terms.

A standard 5-ounce glass of wine at 12% ABV contains approximately 14 grams of ethanol.

A 5-ounce glass of YOURS at 0.5% ABV contains approximately 0.6 grams of ethanol.

The liver processes ethanol at roughly 10 grams per hour. The 0.6 grams of ethanol in a glass of NA wine would be cleared in approximately three to four minutes.

For comparison: a ripe banana contains approximately 0.5 grams of ethanol from natural fermentation. Ripe fruit and fruit juice contain trace ethanol in the same range. The ethanol load from a glass of 0.5% ABV wine is within the normal range of trace dietary ethanol that the liver processes constantly from food sources.

At this dose level, acetaldehyde does not accumulate meaningfully. The NAD+/NADH ratio disruption that initiates fatty liver requires sustained ethanol metabolism. Three to four minutes of processing is not sustained. The hepatocyte protein adducts and inflammatory signaling associated with acetaldehyde toxicity require the acetaldehyde to be present long enough and at high enough concentrations to react. At 0.6 grams of ethanol, neither condition is met.

The ALDH2 pathway still processes the small amount of acetaldehyde produced, but the conversion is complete before any accumulation could occur. This is why 0.5% ABV is the regulatory threshold that determines "non-alcoholic" classification: at this concentration level, the ethanol behaves like dietary trace ethanol, not like an alcoholic beverage's pharmacological dose.

For more on what this number means in practice and how it is measured, see how much alcohol is in non-alcoholic wine.

The Connection to Headaches and Acetaldehyde

One reason the acetaldehyde pathway matters beyond the liver is that acetaldehyde accumulation is associated with symptoms that regular wine drinkers know well. Headaches after drinking, particularly red wine headaches, have multiple proposed mechanisms, but acetaldehyde toxicity is one of the most mechanistically supported.

If acetaldehyde builds up before ALDH2 can clear it, it produces systemic effects including vasodilation, nausea, and headache. This is the same mechanism behind the "Asian flush" response in individuals with ALDH2*2, only at a lower magnitude in people with normal ALDH2 function who drink faster than their liver can clear acetaldehyde.

At 0.5% ABV, the acetaldehyde produced is cleared before accumulation. This is one reason people who switch from standard wine to YOURS report fewer next-morning headaches. The mechanism is specific, not anecdotal. For the fuller picture, see non-alcoholic wine and headaches.

Inflammation as a Connecting Thread

The liver story connects to a broader pattern. Acetaldehyde-driven inflammation in the liver is one part of a systemic inflammatory response that alcohol triggers. The LPS that crosses a compromised gut lining reaches the liver through the portal circulation, where Kupffer cells process it. The liver is not an isolated target. It is the endpoint of an inflammatory cascade that starts in the gut and is driven by the same primary agent: acetaldehyde.

For the gut piece of this pathway, see alcohol and gut health. For the systemic inflammatory picture beyond the liver and gut, see alcohol and inflammation.

Blood pressure is another downstream effect of alcohol-related systemic inflammation and vasomotor disruption. See alcohol and blood pressure for that connection.

Acetaldehyde also plays a central role in cancer risk: it forms DNA adducts in tissues exposed to it, and the World Health Organization classifies it as a Group 1 carcinogen. For the full mechanism, see alcohol and cancer risk.

The Kupffer cell activation described above is also part of a broader immune disruption pathway. Regular alcohol exposure suppresses adaptive immune function and impairs pathogen clearance; the full mechanism is covered in alcohol and immune system.

The relationship between liver metabolism and cholesterol is also direct: alcohol disrupts the hepatic processing of LDL and HDL, producing cardiovascular effects that extend beyond inflammation alone. See alcohol and cholesterol for the lipid-handling detail.

What YOURS Removes and What It Keeps

YOURS is made from real California wine that is then dealcoholized. The fermentation process is complete. The polyphenols, including the resveratrol, quercetin, and anthocyanins that build during fermentation, are retained. These are the compounds with documented antioxidant activity. They are non-volatile and survive the dealcoholization process.

What is removed is the ethanol, and with it, the ADH/ALDH2 metabolic burden. The acetaldehyde production, the NAD+/NADH ratio shift, the hepatocyte protein adducts, the inflammatory signaling. None of that occurs at meaningful levels from 0.6 grams of ethanol.

Under 20 calories per glass. 4 grams of carbs. Zero added sugar. The flavor complexity and antioxidant profile of real California wine, without the metabolic pathway that does the damage.

For more on how the polyphenol profile is preserved through dealcoholization, see non-alcoholic wine polyphenols and antioxidants. For the full process from grape to glass, see how non-alcoholic wine is made.

PAA: Common Questions Answered

How does alcohol damage the liver?

Alcohol damages the liver through a specific biochemical pathway. Alcohol dehydrogenase (ADH) converts ethanol to acetaldehyde, a toxic compound that forms protein adducts in liver cells, triggers inflammatory signaling, and generates reactive oxygen species. The second enzyme in the pathway, ALDH2, converts acetaldehyde to acetate, which is benign. When ethanol intake exceeds the liver's clearance capacity, acetaldehyde accumulates and the damage occurs. Separately, alcohol metabolism depletes NAD+, which inhibits fat burning in the liver and promotes fat accumulation, leading to hepatic steatosis.

What is fatty liver from alcohol?

Hepatic steatosis (fatty liver) is the earliest and most reversible stage of alcohol-related liver disease. It develops because alcohol metabolism consumes NAD+ and produces NADH, shifting the liver's metabolic balance away from fat burning (beta-oxidation) and toward fat synthesis. Lipid accumulates in hepatocytes as a result. Fatty liver can occur at relatively modest consumption levels, research has documented it at two to three drinks per day. It is largely reversible with abstinence.

Can moderate drinking damage the liver?

The research indicates that liver damage from alcohol occurs on a spectrum, and the threshold for measurable effects (particularly fatty liver) is lower than most people assume. Whether moderate drinking (up to one to two drinks per day) produces progressive liver disease in otherwise healthy individuals is more specific, individual genetic factors, particularly ALDH2 efficiency, play a significant role. The claim that moderate drinking protects liver health relative to abstinence has been substantially challenged on methodological grounds and is not established science.

What is the difference between fatty liver, hepatitis, and cirrhosis?

These represent three stages of severity. Fatty liver (steatosis) is lipid accumulation in liver cells from disrupted fat metabolism, reversible with abstinence. Alcoholic steatohepatitis (ASH) adds active inflammation, hepatocyte balloon degeneration, and cell death to the picture, the liver is now being injured, not just loaded with fat. Cirrhosis is the end stage: extensive, irreversible scarring of liver tissue from chronic inflammation activating collagen-producing stellate cells. Each stage is more serious than the previous, and continued alcohol consumption accelerates progression.

What does 0.5% ABV mean for liver health?

At 0.5% ABV, a 5-ounce glass of non-alcoholic wine contains approximately 0.6 grams of ethanol. The liver processes ethanol at approximately 10 grams per hour, meaning this dose is cleared in three to four minutes. Acetaldehyde does not accumulate at this dose level. The NAD+/NADH ratio disruption that initiates fatty liver requires sustained ethanol metabolism that 0.6 grams cannot produce. This ethanol load is comparable to what the liver processes from ripe fruit as a normal dietary input.

Related Reading

• How non-alcoholic wine is made, the dealcoholization process and what it preserves from fermentation
• Alcohol and gut health, the acetaldehyde and intestinal permeability pathway; the LPS that reaches your liver starts in the gut
• Alcohol and inflammation, the systemic inflammatory picture beyond the liver
• Non-alcoholic wine and headaches, the acetaldehyde-headache connection explained
• How much alcohol is in non-alcoholic wine, the 0.5% ABV threshold and what it means in practice
• Alcohol and blood pressure, downstream effects of alcohol-related vascular and inflammatory disruption
• Non-alcoholic wine polyphenols and antioxidants, the antioxidant compounds fermentation builds and dealcoholization preserves
• Alcohol and immune system, how the same Kupffer cell activation and LPS pathway suppresses adaptive immunity
• Alcohol and cholesterol, hepatic lipid processing disruption and the HDL/LDL picture